Identification
- Summary
Epicriptine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.
- Generic Name
- Epicriptine
- DrugBank Accession Number
- DB11275
- Background
Epicriptine is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine. Together with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture. Epicriptine differs from the alpha form on the position of one methyl group.1 To know more about the mixture please visit Ergoloid mesylate
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Epicriptine (DB11275)
- Weight
- Average: 577.726
Monoisotopic: 577.326419505 - Chemical Formula
- C32H43N5O5
- Synonyms
- dihydro-beta-ergocryptine
- Epicriptina
- Epicriptine
- Epicriptinum
- Epicryptine
- External IDs
- Dcn 203-922
Pharmacology
- Indication
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Mechanism of action
Epicriptine effect is mainly due to the agonistic activity on dopamine receptor. This activity is categorized as part of the ergoline class which is defined as a producer of a vasoconstrictive effect.1 Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
Target Actions Organism ADopamine receptor agonistHumans - Absorption
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Volume of distribution
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Protein binding
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Metabolism
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Route of elimination
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Half-life
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Clearance
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Please refer to Ergoloid mesylate and to know more about the isomer please refer to Dihydro-alpha-ergocryptine.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetophenazine The therapeutic efficacy of Epicriptine can be decreased when used in combination with Acetophenazine. Amisulpride The therapeutic efficacy of Epicriptine can be decreased when used in combination with Amisulpride. Amoxapine The therapeutic efficacy of Epicriptine can be decreased when used in combination with Amoxapine. Apomorphine The risk or severity of adverse effects can be decreased when Apomorphine is combined with Epicriptine. Aripiprazole The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Epicriptine. Asenapine The therapeutic efficacy of Epicriptine can be decreased when used in combination with Asenapine. Benperidol The therapeutic efficacy of Epicriptine can be decreased when used in combination with Benperidol. Brexpiprazole The risk or severity of adverse effects can be decreased when Brexpiprazole is combined with Epicriptine. Bromocriptine The risk or severity of adverse effects can be decreased when Bromocriptine is combined with Epicriptine. Buspirone The therapeutic efficacy of Epicriptine can be decreased when used in combination with Buspirone. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Epicriptine mesilate 79Y4U49I29 65914-79-6 YKEUOHBRJUALFI-ILSKZLILSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Ergoloid Mesylates Epicriptine mesilate (0.111 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) Tablet Oral Frontida BioPharm, Inc. 2017-06-01 Not applicable US 
Ergoloid Mesylates Epicriptine mesilate (0.111 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) Tablet Oral Av Kare, Inc. 2014-08-22 2015-09-15 US Ergoloid Mesylates Epicriptine mesilate (0.111 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) Tablet Oral Sun Pharmaceutical Industries Limited 1991-10-31 Not applicable US Ergoloid Mesylates Epicriptine mesilate (0.111 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) Tablet Oral Physicians Total Care, Inc. 1991-10-31 2012-10-08 US Ergoloid Mesylates Epicriptine mesilate (0.111 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) Tablet Oral Carilion Materials Management 1991-10-31 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 5M64643B5U
- CAS number
- 88660-47-3
- InChI Key
- SBFXHXZNBNFPHV-PXXBSISHSA-N
- InChI
- InChI=1S/C32H43N5O5/c1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20/h7,9-10,15,17-18,20,22,24-25,27,33,41H,6,8,11-14,16H2,1-5H3,(H,34,38)/t18-,20-,22-,24-,25+,27+,31-,32+/m1/s1
- IUPAC Name
- (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-[(2R)-butan-2-yl]-2-hydroxy-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
- SMILES
- [H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C
References
- General References
- Steinhilber, D., Schubert M. and Roth H. (2005). Medizinische Chemie. Deutscher Apotheker Verlag. [ISBN:3-7692-3483-9]
- External Links
- ChemSpider
- 59102
- 91171
- ChEBI
- 135927
- ChEMBL
- CHEMBL2106411
- ZINC
- ZINC000004215812
- Wikipedia
- Epicriptine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source boiling point (°C) 848 ºC at 760 mm Hg 'MSDS' - Predicted Properties
Property Value Source Water Solubility 0.276 mg/mL ALOGPS logP 3.39 ALOGPS logP 3.5 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 9.71 Chemaxon pKa (Strongest Basic) 8.39 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 118.21 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 157.26 m3·mol-1 Chemaxon Polarizability 63.58 Å3 Chemaxon Number of Rings 7 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
| Name | UniProt ID |
|---|---|
| D(1A) dopamine receptor | P21728 |
| D(1B) dopamine receptor | P21918 |
| D(2) dopamine receptor | P14416 |
| D(3) dopamine receptor | P35462 |
| D(4) dopamine receptor | P21917 |
References
- Steinhilber, D., Schubert M. and Roth H. (2005). Medizinische Chemie. Deutscher Apotheker Verlag. [ISBN:3-7692-3483-9]
Drug created at December 03, 2015 16:52 / Updated at February 21, 2021 18:53